Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE1A | P54750 | 1/20 | 0.38 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.38 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.38 |
| ▸ | BRD9 | Q9H8M2 | 2/20 | 0.36 |
| ▸ | BRD7 | Q9NPI1 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | FLT3 | P36888 | 2/20 | 0.35 |
| ▸ | GSK3B | P49841 | 1/20 | 0.35 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | RAD52 | P43351 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | NPC1 | O15118 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.34 |
| ▸ | HTT | P42858 | 2/20 | 0.34 |
| ▸ | RAB9A | P51151 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16508297 | 0.83 | CYP3A4 (0.35) | PDE1APDE1BPDE1CKDRFLT3 | |
| SCHEMBL1702817 | 0.83 | CYP3A4 (0.41) | PDE1APDE1BPDE1CBRD9BRD7 | |
| SCHEMBL16508263 | 0.81 | SGK1 (0.39) | MAPTCYP3A4 | |
| SCHEMBL16508270 | 0.78 | MAP3K11 (0.42) | BRD4FLT3CYP3A4 | |
| SCHEMBL16508295 | 0.75 | CYP3A4 (0.49) | CYP3A4DYRK1A | |
| SCHEMBL16508298 | 0.71 | JAK2 (0.34) | PDE1APDE1BPDE1CKDM4EMAPT | |
| SCHEMBL16508299 | 0.71 | CYP3A4 (0.49) | BRD9BRD4KDM4EMAPTHSP90AA1 | |
| SCHEMBL16508264 | 0.69 | CYP3A4 (0.49) | KDM4EMAPTHSP90AA1MAPK1CYP3A4 | |
| SCHEMBL1542385 | 0.68 | CYP3A4 (0.64) | CYP1A1KDM4EMEN1NPC1MAPT | |
| SCHEMBL12331953 | 0.67 | CYP3A4 (0.40) | CYP1A1NPC1RAB9ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | ROCHE PALO ALTO LLC (US) | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300103-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | EIF2AK2, ZC3HAV1, IRF3 | PDE1A 4846/4885PDE1B 4850/4885PDE1C 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.